Skip to menu Skip to content Skip to footer
Professor Paul Griffin
Professor

Paul Griffin

Email: 

Overview

Background

Associate Professor Paul Griffin is the Director of Infectious Diseases at Mater Health Services in Brisbane and Associate Professor of Medicine at the University of Queensland Medical School. He has fellowships in Infectious Diseases from the Royal Australasian College of Physicians, in Clinical Microbiology from the Royal College of Pathologists of Australasia and from the Australasian College of Tropical Medicine.

Paul is the Principal Investigator and Medical Director at Nucleus Network, a specialized contract research organisation specializing in early and late phase trials in infectious diseases where he has been the principal investigator on in excess of 125 clinical trials, predominantly in Infectious Diseases including novel vaccines and Malaria human challenge studies. This includes 8 vaccines for COVID-19 and a number of COVID-19 therapies.

As a Clinical Microbiologist, he maintains an active interest in diagnostic microbiology with a focus on clinical applications of faecal microbiome metagenomic sequencing.

In addition to a teaching role at the University of Queensland, Paul is also the chair of the Advanced Training Committee in Infectious Diseases with the Royal Australasian College of Physicians, the committee that oversees the training of Infectious Diseases specialists in Australia.

Finally, as a director and scientific advisory board member of the immunisation coalition, Paul has an active interest in vaccine education and advocacy and has become a trusted media authority and spokesperson across the nation during the COVID-19 pandemic.

Availability

Professor Paul Griffin is:
Available for supervision
Media expert

Research impacts

While performing vital clinical and research duties, he has also devoted time to inform, educate and reassure the community via a wide range of media appearances. He has featured regularly on prominent Australian programs across television, radio, print and online including The Project, Sunrise, Today Show, A Current Affair, and internationally including Canada’s CTV and the BBC.

Works

Search Professor Paul Griffin’s works on UQ eSpace

87 works between 2010 and 2024

1 - 20 of 87 works

2024

Journal Article

QuantumEyes: Towards Better Interpretability of Quantum Circuits

Ruan, Shaolun, Guan, Qiang, Griffin, Paul, Mao, Ying and Wang, Yong (2024). QuantumEyes: Towards Better Interpretability of Quantum Circuits. IEEE Transactions on Visualization and Computer Graphics, 30 (9), 6321-6333. doi: 10.1109/tvcg.2023.3332999

QuantumEyes: Towards Better Interpretability of Quantum Circuits

2024

Journal Article

Revolutionising RSV infection prevention and control Unveiling new options in the fight against RSV

Spence, Luke, Armstrong, Mark R. and Griffin, Paul M. (2024). Revolutionising RSV infection prevention and control Unveiling new options in the fight against RSV. Medicine Today, 25 (7), 45-54.

Revolutionising RSV infection prevention and control Unveiling new options in the fight against RSV

2024

Journal Article

<i>VIOLET</i>: <u>V</u>isual Analyt<u>i</u>cs f<u>o</u>r Exp<u>l</u>ainable Quantum N<u>e</u>ural Ne<u>t</u>works

Ruan, Shaolun, Liang, Zhiding, Guan, Qiang, Griffin, Paul, Wen, Xiaolin, Lin, Yanna and Wang, Yong (2024). VIOLET: Visual Analytics for Explainable Quantum Neural Networks. IEEE Transactions on Visualization and Computer Graphics, 30 (6), 2862-2874. doi: 10.1109/tvcg.2024.3388557

<i>VIOLET</i>: <u>V</u>isual Analyt<u>i</u>cs f<u>o</u>r Exp<u>l</u>ainable Quantum N<u>e</u>ural Ne<u>t</u>works

2024

Journal Article

Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target

Sasso, Etianne Martini, Muraki, Katsuhiko, Eaton-Fitch, Natalie, Smith, Peter, Jeremijenko, Andrew, Griffin, Paul and Marshall-Gradisnik, Sonya (2024). Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target. Frontiers in Immunology, 15. doi: 10.3389/fimmu.2024.1264702

Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target

2024

Journal Article

Seasonal vaccination Bracing for winter

Armstrong, Mark R., Spence, Luke and Griffin, Paul M. (2024). Seasonal vaccination Bracing for winter. Medicine Today, 25 (5), 12-18.

Seasonal vaccination Bracing for winter

2024

Journal Article

Bracing for impact Navigating the complexities of the 2024 influenza season in Australia

Spence, Luke, Armstrong, Mark R. and Griffin, Paul M. (2024). Bracing for impact Navigating the complexities of the 2024 influenza season in Australia. Medicine Today, 25 (5), 39-48.

Bracing for impact Navigating the complexities of the 2024 influenza season in Australia

2024

Journal Article

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness

Plotnik, David, Sager, Jennifer E., Aryal, Madhukar, Fanget, Marie C., Peter, Alessia, Schmid, Michael A., Cebrik, Deborah, Mogalian, Erik, Boundy, Keith, Yeh, Wendy W., Griffin, Paul and Reyes, Maribel (2024). A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness. Antimicrobial Agents and Chemotherapy, 68 (4). doi: 10.1128/aac.01273-23

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness

2024

Journal Article

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

Bennett, Chijioke, Woo, Wayne, Bloch, Mark, Cheung, King, Griffin, Paul, Mohan, Rahul, Deshmukh, Sachin, Arya, Mark, Cumming, Oscar, Neville, A Munro, McCallum Pardey, Toni G, Plested, Joyce S, Cloney-Clark, Shane, Zhu, Mingzhu, Kalkeri, Raj, Patel, Nita, Marcheschi, Alex, Swan, Jennifer, Smith, Gale, Cho, Iksung, Glenn, Gregory M, Walker, Robert, Mallory, Raburn M, Anderson, Anna, Ang, Mary, Barnes, Timothy, Bassin, Michelle, Bessey, Kate, Bowler, Simon ... Young, Rhys (2024). Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial. The Lancet Infectious Diseases, 24 (6), 581-593. doi: 10.1016/S1473-3099(24)00077-X

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

2023

Journal Article

Immunogenicity and safety of heterologous omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3 randomized clinical trial

Bennett, Chijioke, Rivers, E. Joy, Woo, Wayne, Bloch, Mark, Cheung, King, Griffin, Paul, Mohan, Rahul, Deshmukh, Sachin, Arya, Mark, Cumming, Oscar, Neville, A. Munro, Pardey, Toni McCallum, Plested, Joyce S., Cloney-Clark, Shane, Zhu, Mingzhu, Kalkeri, Raj, Patel, Nita, Buchanan, Agi, Marcheschi, Alex, Swan, Jennifer, Smith, Gale, Cho, Iksung, Glenn, Gregory M., Walker, Robert and Mallory, Raburn M. (2023). Immunogenicity and safety of heterologous omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3 randomized clinical trial. Journal of Infectious Diseases, 230 (1), e4-e16. doi: 10.1093/infdis/jiad508

Immunogenicity and safety of heterologous omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3 randomized clinical trial

2023

Journal Article

Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial

Chappell, Keith J., Mordant, Francesca L., Amarilla, Alberto A., Modhiran, Naphak, Liang, Benjamin, Li, Zheyi, Wijesundara, Danushka K., Lackenby, Julia A., Griffin, Paul, Bennet, Jillian K., Hensen, Luca, Zhang, Wuji, Nguyen, Thi H.O., Tran, Mai H., Tapley, Peter, Barnes, James, Reading, Patrick C., Kedzierska, Katherine, Ranasinghe, Charani, Subbarao, Kanta, Watterson, Daniel, Young, Paul R. and Munro, Trent P. (2023). Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial. eBioMedicine, 97 104842. doi: 10.1016/j.ebiom.2023.104842

Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial

2023

Journal Article

Strong CD4+T-cell responses to ancestral and variant spike proteins are established by NVX-CoV2373 severe acute respiratory syndrome Coronavirus 2 primary vaccination

Fries, Louis, Formica, Neil, Mallory, Raburn M, Zhou, Haixia, Plested, Joyce S, Kalkeri, Raj, Moldovan, Ioana, Patel, Nita, Albert, Gary, Robinson, Michelle, Cho, Iksung, Chau, Gordon, Dubovsky, Filip, Glenn, Gregory M, Adams, Mark, Arya, Mark, Athan, Eugene, Berger, Ira, Bradley, Paul, Glover, Richard, Griffin, Paul, Kim, Joshua, Kitchener, Scott, Klein, Terry, Leah, Amber, Lemech, Charlotte, Lickliter, Jason, Manning, Mary Beth, Napier-Flood, Fiona ... Turner, Mark (2023). Strong CD4+T-cell responses to ancestral and variant spike proteins are established by NVX-CoV2373 severe acute respiratory syndrome Coronavirus 2 primary vaccination. Journal of Infectious Diseases, 228 (6), 734-741. doi: 10.1093/infdis/jiad163

Strong CD4+T-cell responses to ancestral and variant spike proteins are established by NVX-CoV2373 severe acute respiratory syndrome Coronavirus 2 primary vaccination

2023

Journal Article

Barriers to optimal management of syphilis in pregnancy and congenital syphilis in south-east Queensland: a qualitative investigation

Fowler, James A., Warzywoda, Sarah, Nourse, Clare, Wu, Mandy, Britton, Sumudu, Rowling, Diane, Griffin, Paul, Lazarou, Mattea, Hamilton, Zoe and Dean, Judith A. (2023). Barriers to optimal management of syphilis in pregnancy and congenital syphilis in south-east Queensland: a qualitative investigation. Sexual Health, 20 (6), 506-513. doi: 10.1071/sh23119

Barriers to optimal management of syphilis in pregnancy and congenital syphilis in south-east Queensland: a qualitative investigation

2023

Journal Article

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

de Bruyn, Guy, Wang, Joyce, Purvis, Annie, Ruiz, Martin Sanchez, Adhikarla, Haritha, Alvi, Saad, Bonaparte, Matthew I., Brune, Daniel, Bueso, Agustin, Canter, Richard M., Ceregido, Maria Angeles, Deshmukh, Sachin, Diemert, David, Finn, Adam, Forrat, Remi, Fu, Bo, Gallais, Julie, Griffin, Paul, Grillet, Marie-Helene, Haney, Owen, Henderson, Jeffrey A., Koutsoukos, Marguerite, Launay, Odile, Torres, Federico Martinon, Masotti, Roger, Michael, Nelson L., Park, Juliana, Rivera-Medina, Doris Maribel, Romanyak, Natalya ... Davis, Yvonne (2023). Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study. eClinicalMedicine, 62 102109, 102109. doi: 10.1016/j.eclinm.2023.102109

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

2023

Journal Article

Syphilis in pregnancy: a qualitative investigation of healthcare provider perspectives on barriers to syphilis screening during pregnancy in south-east Queensland

Warzywoda, Sarah, Fowler, James A., Nourse, Clare, Wu, Mandy, Britton, Sumudu, Rowling, Diane, Griffin, Paul, Lazarou, Mattea, Hamilton, Zoe and Dean, Judith A. (2023). Syphilis in pregnancy: a qualitative investigation of healthcare provider perspectives on barriers to syphilis screening during pregnancy in south-east Queensland. Sexual Health, 20 (4), 330-338. doi: 10.1071/sh22193

Syphilis in pregnancy: a qualitative investigation of healthcare provider perspectives on barriers to syphilis screening during pregnancy in south-east Queensland

2023

Journal Article

Expanding the geographic boundaries of Melioidosis in Queensland, Australia

Gassiep, Ian, Grey, Victoria, Thean, Li Jun, Farquhar, Drew, Clark, Julia E., Ariotti, Lawrence, Graham, Rikki, Jennison, Amy V., Bergh, Haakon, Anuradha, Satyamurthy, Dyer, Wendy, James, Christian, Huang, Andrea, Putt, Elise, Pakeerathan, Veenaa, Griffin, Paul M. and Harris, Patrick N. A. (2023). Expanding the geographic boundaries of Melioidosis in Queensland, Australia. The American Journal of Tropical Medicine and Hygiene, 108 (6), 1215-1219. doi: 10.4269/ajtmh.23-0002

Expanding the geographic boundaries of Melioidosis in Queensland, Australia

2023

Journal Article

Improving care for patients with Clostridioides difficile infection: A clinical practice and healthcare systems perspective

Hocking, Lucy, Wilcox, Mark, Petrosillo, Nicola, Griffin, Paul, Steiner, Theodore, Attara, Gail, Doré, Joel, Cabling, Mark, Stockwell, Stephanie, Romanelli, Robert J. and Marjanovic, Sonja (2023). Improving care for patients with Clostridioides difficile infection: A clinical practice and healthcare systems perspective. Frontiers in Medicine, 9 1033417, 1-21. doi: 10.3389/fmed.2022.1033417

Improving care for patients with Clostridioides difficile infection: A clinical practice and healthcare systems perspective

2022

Journal Article

Longitudinal transitions in tobacco use in youth and young adults: A latent transition analysis of the population assessment of tobacco and health study from Wave 1 to 5

Huang, Siyi, Chen, Qiushi, Griffin, Paul, Liu, Guodong and Azagba, Sunday (2022). Longitudinal transitions in tobacco use in youth and young adults: A latent transition analysis of the population assessment of tobacco and health study from Wave 1 to 5. Addictive Behaviors, 138 ARTN 107548. doi: 10.1016/j.addbeh.2022.107548

Longitudinal transitions in tobacco use in youth and young adults: A latent transition analysis of the population assessment of tobacco and health study from Wave 1 to 5

2022

Journal Article

A multinational Delphi consensus to end the COVID-19 public health threat

Lazarus, Jeffrey V., Romero, Diana, Kopka, Christopher J., Karim, Salim Abdool, Abu-Raddad, Laith J., Almeida, Gisele, Baptista-Leite, Ricardo, Barocas, Joshua A., Barreto, Mauricio L., Bar-Yam, Yaneer, Bassat, Quique, Batista, Carolina, Bazilian, Morgan, Chiou, Shu-Ti, del Rio, Carlos, Dore, Gregory J., Gao, George F., Gostin, Lawrence O., Hellard, Margaret, Jimenez, Jose L., Kang, Gagandeep, Lee, Nancy, Matičič, Mojca, McKee, Martin, Nsanzimana, Sabin, Oliu-Barton, Miquel, Pradelski, Bary, Pyzik, Oksana, Rabin, Kenneth ... Øvrehus, Anne (2022). A multinational Delphi consensus to end the COVID-19 public health threat. Nature, 611 (7935), 332-345. doi: 10.1038/s41586-022-05398-2

A multinational Delphi consensus to end the COVID-19 public health threat

2022

Journal Article

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Mallory, Raburn M., Formica, Neil, Pfeiffer, Susan, Wilkinson, Bethanie, Marcheschi, Alex, Albert, Gary, McFall, Heather, Robinson, Michelle, Plested, Joyce S., Zhu, Mingzhu, Cloney-Clark, Shane, Zhou, Bin, Chau, Gordon, Robertson, Andreana, Maciejewski, Sonia, Hammond, Holly L., Baracco, Lauren, Logue, James, Frieman, Matthew B., Smith, Gale, Patel, Nita, Glenn, Gregory M., Adams, Mark, Arya, Mark, Athan, Eugene, Berger, Ira, Bradley, Paul, Briskin, Toby, Glover II, Richard ... Turner, Mark (2022). Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases, 22 (11), 1565-1576. doi: 10.1016/S1473-3099(22)00420-0

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

2022

Book

Frontiers of COVID-19: Scientific and clinical aspects of the novel coronavirus 2019

Sasan Adibi, Paul Griffin, Melvin Sanicas, Maryam Rashidi and Francesco Lanfranchi eds. (2022). Frontiers of COVID-19: Scientific and clinical aspects of the novel coronavirus 2019. Cham, Switzerland: Springer. doi: 10.1007/978-3-031-08045-6

Frontiers of COVID-19: Scientific and clinical aspects of the novel coronavirus 2019

Funding

Past funding

  • 2019 - 2023
    Syphilis in pregnant women and their newborn infants in South-East Queensland 2016-202: A retrospective review of management and outcomes and evaluation of barriers to care
    Children's Health Queensland Hospital and Health Service
    Open grant

Supervision

Availability

Professor Paul Griffin is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Media

Enquiries

Contact Professor Paul Griffin directly for media enquiries about:

  • COVID-19
  • Infectious Diseases
  • microbiology
  • Vaccines

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au